Meghan G. McReynolds

Apr 29, 2024 | nature.com | Raymond Carter |Baranda S. Hansen |Katherine A. Donovan |Moritz Hunkeler |Wojciech Rosikiewicz |Meghan G. McReynolds | +8 more

Correction to: Nature https://doi.org/10.1038/s41586-024-07250-1 Published online 27 March 2024In the version of the article initially published, the far-right labels in Fig. 4h (now reading “Viable cells” and “Lethal in SMARCB1-deficient RT cells”) were swapped and have now been corrected in the HTML and PDF versions of the article. About this articleRadko-Juettner, S., Yue, H., Myers, J.A. et al. Author Correction: Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF.

Mar 27, 2024 | nature.com | Raymond Carter |Baranda S. Hansen |Katherine A. Donovan |Moritz Hunkeler |Wojciech Rosikiewicz |Nada Mageed | +8 more

AbstractWhereas oncogenes can potentially be inhibited with small molecules, the loss of tumour suppressors is more common and is problematic because the tumour-suppressor proteins are no longer present to be targeted. Notable examples include SMARCB1-mutant cancers, which are highly lethal malignancies driven by the inactivation of a subunit of SWI/SNF (also known as BAF) chromatin-remodelling complexes.